As mentioned above, as UFT can prevent ER-positive breast cancer from recurring when combined with hormone therapy, regardless of HER2 status, it may provide a useful therapeutic option for patients with intermediate-risk breast cancer. The gene discussed is ERBB2; the disease is breast cancer.